Iterum Therapeutics Q2 net loss $12.2M; REASSURE trial 50% enrolled, topline data expected Q2 2024

Iterum Therapeutics plc

2023-Q2 EPS reported -$1.73

Net loss $12.2M in Q2 2023 vs $6.7M in Q2 2022; non-GAAP net loss $10.0M.
R&D expense $9.0M (up from $4.0M) driven by REASSURE trial costs; G&A $1.9M (down from $4.1M).
Cash and short-term investments $44.7M; cash runway into Q3 2024.
REASSURE trial: 50% enrollment (target 1,966 patients); enrollment completion expected Q1 2024, topline data Q2 2024.
New Japanese patent for oral sulopenem bilayer tablet granted; expires no earlier than 2039.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Iterum Therapeutics plc reported quarter ended June 30, 2023 results: net income $12.2 million.

Period: quarter ended June 30, 2023
Net income: $12.2 million
Result: reported results

Exact text from the filing

Iterum Therapeutics plc issued a press release announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-23-041597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.